Adalimumab

This information is for anyone with Crohn’s Disease or Ulcerative Colitis (the two main forms of Inflammatory Bowel Disease - IBD) who is considering, or has started, treatment with adalimumab. Adalimumab is also known as Humira or the biosimilars Amgevita, Hyrimoz, Imraldi, and Hulio.

It looks at:
• how the drug works
• what you can expect from treatment
• possible side effects
• stopping or changing treatment.

The information also aims to help you talk to your IBD team about the possible benefits and risks of adalimumab. And ask all the questions you need to make an informed decision about your treatment.

Other names for this medicine
Why am I being offered treatment with adalimumab?
How effective is adalimumab?
How does it work?
How long will it take to work?
How do I take adalimumab?
Tips on injecting adalimumab
What is the normal dosage?
How long will I be taking it?
Stopping or changing treatment
Can adalimumab be used in combination with other drugs to treat Crohn's or Colitis?
Do I need any checks before I start treatment?
Will I need ongoing checks?
Will I need to take any special precautions while being treated with adalimumab?
What are the most likely side effects of adalimumab?
Can I have immunisations while on adalimumab?
Is it safe to take other medications along with adalimumab?
Does adalimumab affect pregnancy?
What about breastfeeding?
Can I drink alcohol while taking adalimumab?
Who should I talk to if I'm worried?
Help and support from Crohn's & Colitis UK
How we write our information

Last reviewed: January 2019